Nicholas Boddicker
Has grant
Research Associate
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Genetic Epidemiology of Lymphoma: Risk and Heterogeneity
Open Date: 2026-10-01
Close Date: 2027-09-30
Articles (17)
Year:
2026
Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Year:
2025
Purpose: Germline pathogenic variants (PV) in ATM increase the risk of pancreatic ductal adenocarcinoma (PDAC), but the underlying tumor biology of PDAC associated with germline PV in ATM has not been adequately explored. Experimental Design: Whole-genome, whole-exome, and RNA sequencing were performed on PDAC tumors from 25 germline ATM PV carriers diagnosed at Mayo Clinic between 2007 and 2017. Somatic and copy-number alterations, mutational signatures, transcriptomic subtypes, and the immune landscape were evaluated. Results: High-quality whole-exome and whole-genome sequencing were obtained from 21 and 15 tumors, respectively. Biallelic inactivation of ATM was observed in 87%, KRAS PV in 90%, CDKN2A homozygous loss in 60%, and TP53 alterations in <10% of these tumors. A predominant clock-like mutational signature was present in all samples. Whole-transcriptome analysis identified that the aberrantly differentiated endocrine exocrine subtype accounted for 18% of PDAC and was consistently associated with >5-year overall survival. In addition, a 28-gene expression–based signature associated with overall survival was identified and further validated in The Cancer Genome Atlas cohort. Immune landscape analysis through CODEX identified enriched CD4 T-helper cell/tumor interactions and reduced B7H3-high cell/tumor interactions in ATM PV carriers compared with noncarriers. Conclusions: The observed absence of TP53 PV and enrichment for CDKN2A alterations in ATM tumors, along with differences in the mutational signatures, transcriptomic subtypes and immune landscape, improve our understanding of the mechanistic pathways involved in PDAC development in germline ATM PV carriers and help identify potential targeted therapeutic strategies.
Year:
2025
Monoclonal B-cell lymphocytosis (MBL) and clonal hematopoiesis of indeterminate potential (CHIP) are prevalent clonal precursors associated with increased risk of lymphoid malignancies. However, the relationship between MBL and CHIP and their combined impact on lymphoid malignancy risk remains poorly understood. We screened participants from the Mayo Clinic Biobank to identify MBL using eight-color flow cytometry; CHIP was detected using whole-exome sequencing of whole-blood DNA in 291 genes related to myeloid or lymphoid malignancies. Incident myeloid or lymphoid hematological malignancies were identified using ICD codes and confirmed via medical record review. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Cox regression was used to estimate hazard ratios (HR). Analyses were adjusted for age and sex. In 10,067 participants, 15% had MBL, and 9% had CHIP. No evidence of an association between MBL and CHIP (OR = 1.00; 95% CI: 0.82–1.20) was observed. With a median follow-up of 5.4 years, 138 participants developed hematological malignancies (94 lymphoid). MBL (HR = 3.48; 95% CI: 2.27–5.34; P < 0.001) and CHIP (HR = 1.89; 95% CI: 1.10–3.27; P = 0.022) were each associated with incident lymphoid malignancy. Compared to individuals with no precursors, the combined presence of MBL and CHIP significantly amplified lymphoma risk (HR = 7.18; 95% CI: 3.33–15.47; P < 0.001), more than doubling the risk among individuals with MBL alone (HR = 3.30; 95% CI: 2.06–5.30; P < 0.001). In contrast, the risk associated with CHIP alone was attenuated and no longer statistically significant (HR = 1.63; 95% CI: 0.77–3.47; P = 0.20). MBL and CHIP are independent hematological precursor conditions. While their combined presence amplifies the risk of lymphoid malignancy, CHIP alone may not be a strong independent risk factor.
Year:
2025
We investigated the prevalence of rare inherited pathogenic variants (PV) in 19 cancer predisposition genes regularly included on multi-gene panel testing based on NCCN guidelines and their association with the risk of lymphoid malignancies (LM) overall and by common lymphoma subtypes and multiple myeloma. The study population included newly diagnosed LM cases ( N = 6990) and unrelated controls ( N = 42,632), excluding individuals with a history of hematologic malignancy. Whole exome sequencing was performed on DNA from whole blood. PV were defined as loss-of-function (i.e., nonsense, frameshift, consensus splice sites) or identified as “pathogenic” or “likely pathogenic” in the ClinVar database. A total of 1816 (3.7%) individuals had a PV across the 19 genes, higher in cases (4.7%) than controls (3.5%). In controls, CHEK2 (1.0%), ATM (0.4%), BRCA2 (0.4%), and BRCA1 (0.3%) had the highest prevalence. ATM (odds ratio [OR] = 1.86, 95% confidence interval [CI]: 1.36–2.49), CHEK2 (OR = 1.74, 95% CI: 1.42–2.13) and TP53 (OR = 9.07, 95% CI: 4.51–18.87) were associated with increased risk of LM overall and were further validated in the UK Biobank. We observed heterogeneity in associations by LM subtype. These results demonstrate that several commonly tested cancer predisposition genes are associated with an increased risk of LM.
Year:
2025
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
Year:
2025
Supplementary figures displaying supporting evidence Supplemental Figure 1: Results of IHC Staining for ATM expression. Supplemental Figure 2: Variant Summary from Whole Exome Sequencing Supplemental Figure 3: Oncoprint of Somatic Mutations. Supplemental Figure 4: Circos Plot of Copy Number Changes and Structural Arrangements Supplemental Figure 5: Single Base Substitution Profile. Supplemental Figure 6: Single Base Substitution Profile for each Tumor Evaluated through Whole Exome Sequencing Supplemental Figure 7. Characterization of Single Base Substitution Mutational Signatures in Pancreatic Tumors from Germline ATM Carriers based on Whole Genome Sequencing Supplemental Figure 8: Single Base Substitution Profile for each Tumor Evaluated through Whole Genome Sequencing Supplemental Figure 9: Transcriptomic Subtypes of Pancreatic Ductal Adenocarcinoma in germline ATM carriers based on Non-negative Matrix Factorization. Supplemental Figure 10: Transcriptomic Subtypes of Pancreatic Ductal Adenocarcinoma in germline ATM carriers based on predefined genesets Supplemental Figure 11. Heatmap of Tumor and Immune Cell Interactions for Pancreatic Ductal Adenocarcinoma in ATM Pathogenic Variant Carriers and Non-carriers Supplemental Figure 12: Comparison of Tumor and Immune Cell Interactions between ATM Pathogenic Variant Carriers and Non-Carriers
Year:
2025
Purpose: Germline pathogenic variants (PV) in ATM increase the risk of pancreatic ductal adenocarcinoma (PDAC), but the underlying tumor biology of PDAC associated with germline PV in ATM has not been adequately explored. Experimental Design: Whole-genome, whole-exome, and RNA sequencing were performed on PDAC tumors from 25 germline ATM PV carriers diagnosed at Mayo Clinic between 2007 and 2017. Somatic and copy-number alterations, mutational signatures, transcriptomic subtypes, and the immune landscape were evaluated. Results: High-quality whole-exome and whole-genome sequencing were obtained from 21 and 15 tumors, respectively. Biallelic inactivation of ATM was observed in 87%, KRAS PV in 90%, CDKN2A homozygous loss in 60%, and TP53 alterations in 5-year overall survival. In addition, a 28-gene expression–based signature associated with overall survival was identified and further validated in The Cancer Genome Atlas cohort. Immune landscape analysis through CODEX identified enriched CD4 T-helper cell/tumor interactions and reduced B7H3-high cell/tumor interactions in ATM PV carriers compared with noncarriers. Conclusions: The observed absence of TP53 PV and enrichment for CDKN2A alterations in ATM tumors, along with differences in the mutational signatures, transcriptomic subtypes and immune landscape, improve our understanding of the mechanistic pathways involved in PDAC development in germline ATM PV carriers and help identify potential targeted therapeutic strategies.
Year:
2025
Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes ( ATM , BARD1 , BRCA1 , BRCA2 , CDH1 , CHEK2 , PALB2 , RAD51C , and RAD51D ) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort ( n = 9,887), a population-based cohort ( n = 3,876), and the UK Biobank ( n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1 , BRCA2 , and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Year:
2025
Pathogenic protein-truncating variants of RAD51C , which plays an integral role in promoting DNA damage repair, increase the risk of breast and ovarian cancer. A large number of RAD51C missense variants of uncertain significance (VUS) have been identified, but the effects of the majority of these variants on RAD51C function and cancer predisposition have not been established. Here, analysis of 173 missense variants by a homology-directed repair (HDR) assay in reconstituted RAD51C −/− cells identified 30 nonfunctional (deleterious) variants, including 18 in a hotspot within the ATP-binding region. The deleterious variants conferred sensitivity to cisplatin and olaparib and disrupted formation of RAD51C/XRCC3 and RAD51B/RAD51C/RAD51D/XRCC2 complexes. Computational analysis indicated the deleterious variant effects were consistent with structural effects on ATP-binding to RAD51C. A subset of the variants displayed similar effects on RAD51C activity in reconstituted human RAD51C -depleted cancer cells. Case–control association studies of deleterious variants in women with breast and ovarian cancer and noncancer controls showed associations with moderate breast cancer risk [OR, 3.92; 95% confidence interval (95% CI), 2.18–7.59] and high ovarian cancer risk (OR, 14.8; 95% CI, 7.71–30.36), similar to protein-truncating variants. This functional data supports the clinical classification of inactivating RAD51C missense variants as pathogenic or likely pathogenic, which may improve the clinical management of variant carriers. Significance: Functional analysis of the impact of a large number of missense variants on RAD51C function provides insight into RAD51C activity and information for classification of the cancer relevance of RAD51C variants.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (70)
Jean Yves Masson
Full Professor
Université Laval Faculté de médecine
James Cerhan
Professor of Epidemiology
Mayo Clinic Rochester
Tomáš Zima
Head of Institute
Charles University and General University Hospital in Prague, First Faculty of Medicine
Kathleen Claes
Full professor
Ghent University Hospital
Giuseppe Matullo
-
Lisa Wiesmüller
Professor
Ulm University
Christopher A. Haiman
University of Southern California
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Jacques Simard
Full Professor
Laval University
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Sara González
Institut Català d'Oncologia
FEI CHEN
Assistant Professor
University of Southern California
Katie O'Brien
Staff Scientist
National Institute of Environmental Health Sciences
A Heather Eliassen
Professor
Harvard University
Irene Ong
Associate Professor
University of Wisconsin-Madison
Alexandra Martins
INSERM
Dale Sandler
Branch Chief
National Institute of Environmental Health Sciences
Julie R Palmer
Boston University School of Medicine
Clarice Weinberg
Principal Investigator
National Institute of Environmental Health Sciences
Alexander E Volk
-
Daniel D. Billadeau
-
gaofeng cui
Assistant professor
Mayo Clinic
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Kari Rabe
Assistant Professor of Biostatistics
Mayo Clinic
Adrian V. Lee
University of Pittsburgh
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Rosalie Griffin
Assistant Professor
The University of Texas MD Anderson Cancer Center
Mariarosaria Calvello
European Institute of Oncology
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Robert McWilliams
Mayo Clinic Minnesota
Maria Elena. Martinez
University of California
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Yuan-Ping Pang
Professor of Biophysics and Pharmacology
Mayo Clinic
Gareth Evans
The University of Manchester
Esther John
Professor
Stanford University School of Medicine
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Paul Auer
Professor
Medical College of Wisconsin
Hoda Anton-Culver
Professor and Chair
University of California, Irvine
Maegan Roberts
Assistant Professor
Ohio State University
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Corinna Ernst
Hannover Medical School
Steven Hart
Mayo Clinic
Allison W Kurian
Professor
Stanford University School of Medicine
Kathryn Ruddy
Professor
Mayo Clinic
Lidia Feliubadaló
Institut Català d'Oncologia
Koichi Matsuda
University of Tokyo
Kimberly A. Bertrand
Associate Professor of Medicine
Boston University
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Eric Polley
Associate Professor
University of Chicago
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Amanda Toland
Ohio State University
Argyrios Ziogas
Professor
University of California, Irvine
Laura Cortesi
University of Modena and Reggio Emilia
Make your next move.
Prepare your application
Review drafts before you send them.